secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001650664-25-000148
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports in vivo proof-of-concept for EDIT-401 with ≥90% LDL-C reduction in NHPs
--------------------------------------------------------------------------------

- EDIT-401 achieved ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose.
- Same ≥90% LDL-C reduction observed in mice with high baseline LDL-C and reduced LDLR function.
- LDL-C reductions maintained in mouse models over a three-month study.
- ≥6-fold mean increase in LDLR protein in NHP liver, requiring only moderate functional editing of LDLR alleles.
- Data presented at ESGCT 32nd Annual Congress; no financial guidance or regulatory milestones changed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000148/0001650664-25-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000148/edit-20251009.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer